| 1.09 -0.15 (-12.1%) | 11-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.35  |
1-year : | 1.55 |
| Resists | First : | 1.16 |
Second : | 1.33 |
| Pivot price | 1.02 |
|||
| Supports | First : | 0.89 |
Second : | 0.74 |
| MAs | MA(5) : | 1.05 |
MA(20) : | 1.05 |
| MA(100) : | 1.34 |
MA(250) : | 1.28 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 68.8 |
D(3) : | 53.9 |
| RSI | RSI(14): 50.3 |
|||
| 52-week | High : | 2.59 | Low : | 0.8 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NRSN ] has closed below upper band by 30.9%. Bollinger Bands are 20.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.27 - 1.28 | 1.28 - 1.28 |
| Low: | 1.04 - 1.04 | 1.04 - 1.05 |
| Close: | 1.08 - 1.09 | 1.09 - 1.1 |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Mon, 03 Nov 2025
NeuroSense (NASDAQ: NRSN) sets Dec. 8, 2025 investor webinar on ALS PARAGON, Canada NOC/c - Stock Titan
Mon, 03 Nov 2025
NeuroSense to Host Investor Webinar on December 8, 2025 - Sahm
Thu, 25 Sep 2025
NeuroSense Therapeutics Approves Resolutions at Annual Meeting - TipRanks
Thu, 04 Sep 2025
40% Premium Investment: Neurodegenerative Biotech NeuroSense Lands Strategic $500K Private Placement - Stock Titan
Thu, 04 Sep 2025
NeuroSense Therapeutics Reports Promising Phase 2b Study Results for ALS Treatment - TipRanks
Thu, 04 Sep 2025
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 25.5 (%) |
| Held by Institutions | 1.2 (%) |
| Shares Short | 270 (K) |
| Shares Short P.Month | 536 (K) |
| EPS | -0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -303.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -3.03 |
| PEG Ratio | 0 |
| Price to Book value | -54.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|